Emergent BioSolutions Inc (EBS.N)
Tue, Aug 28 2018
Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.
* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)
Aug 28 Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.
* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
BRIEF-Emergent BioSolutions Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer
* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY
* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK